Back to funds

BAKER BROS. ADVISORS LP

Updated 6 days ago

Managed by Baker Bros. Advisors Lp • Latest filing Q3 2026

Portfolio value
$21B
Q3 2026
Filings
4
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
—
Implied from 13F holdings

Portfolio value history

13F-disclosed portfolio value over 4 quarters

Show data table
PeriodPortfolio value
Q4 2025$17.1B
Q1 2026$17.4B
Q2 2026$20B
Q3 2026$21B

Top holdings

80 positions as of Q3 2026

View filing
I

Incyte Corporation

Value
$3.7B
Shares
30.76M
% Port
17.74%
B

BeOne Medicines Ltd.

Value
$3.2B
Shares
8.83M
% Port
15.36%
R

Revolution Medicines, Inc.

Value
$2.2B
Shares
10.64M
% Port
10.38%
K

Kodiak Sciences Inc.

Value
$2.1B
Shares
21.86M
% Port
9.85%
M

Madrigal Pharmaceuticals, Inc.

Value
$1.1B
Shares
2.14M
% Port
5.13%
I

Insmed Incorporated

Value
$1B
Shares
8.80M
% Port
4.77%
K

Kymera Therapeutics, Inc.

Value
$967.8M
Shares
8.66M
% Port
4.60%
A

ACADIA Pharmaceuticals Inc.

Value
$864.7M
Shares
42.91M
% Port
4.11%
G

GRAIL, Inc.

Value
$564.5M
Shares
4.03M
% Port
2.68%
S

Summit Therapeutics Inc.

Value
$554.4M
Shares
32.79M
% Port
2.63%
R

Rhythm Pharmaceuticals, Inc.

Value
$533.6M
Shares
5.60M
% Port
2.54%
P

Praxis Precision Medicines, Inc.

Value
$510.6M
Shares
1.75M
% Port
2.43%
A

AbCellera Biologics Inc.

Value
$481.6M
Shares
33.01M
% Port
2.29%
A

Alkermes plc

Value
$405.7M
Shares
10.01M
% Port
1.93%
C

Celcuity Inc.

Value
$383M
Shares
4.82M
% Port
1.82%
K

Kiniksa Pharmaceuticals International, plc

Value
$211.5M
Shares
2.83M
% Port
1.00%
I

IDEAYA Biosciences, Inc.

Value
$192.5M
Shares
5.01M
% Port
0.91%
E

Edgewise Therapeutics, Inc.

Value
$150.3M
Shares
3.70M
% Port
0.71%
Q

Replimune Group, Inc.

Value
$146.2M
Shares
11.05M
% Port
0.69%
R

Roivant Sciences Ltd.

Value
$133.9M
Shares
3.66M
% Port
0.64%

Explore